ライフサイエンスコーパス: glucose level

1 ions that can raise or reduce falls in blood glucose level.

2 and concomitantly reduced appetite and body glucose level.

3 on being altered depending on maternal blood glucose level.

4 cardiometabolic outcomes, including fasting glucose level.

5 lin secretion in response to increased brain glucose level.

6 enabling potential seamless control of blood glucose level.

7 index, systolic blood pressure, and fasting glucose level.

8 e number of free islets was unable to affect glucose levels.

9 rides, might have a causal role of elevating glucose levels.

10 e, baseline ischemic core volume on CTP, and glucose levels.

11 simple and less invasive monitoring of blood glucose levels.

12 despite improving plasma lipids and fasting glucose levels.

13 lock genes and perturbs whole-body lipid and glucose levels.

14 c low-grade inflammation and elevated plasma glucose levels.

15 n secretion only in the presence of elevated glucose levels.

16 There was no difference in glucose levels.

17 y glucose >/=1.13 mg/dL were defined as high glucose levels.

18 o observed after subjects were stratified by glucose levels.

19 ves the release of hormones to restore blood glucose levels.

20 inated upon exposure of beta-cells to normal glucose levels.

21 the number of daily sleep hours and salivary glucose levels.

22 n in glucagon secretion observed at elevated glucose levels.

23 the liver injury and normalization of blood glucose levels.

24 ple, blood permittivity depends on the blood glucose levels.

25 Institutes of Health Stroke Scale score, and glucose levels.

26 xicity and is associated with improved blood glucose levels.

27 y of hormones that precisely regulate plasma glucose levels.

28 in secretion from islets exposed to elevated glucose levels.

29 , increase glucose excretion and lower blood glucose levels.

30 HFD/STZ]) to induce a mild increase in blood glucose levels.

31 was observed without any reduction in blood glucose levels.

32 diastolic dysfunction, and normalized blood glucose levels.

33 141795 did not significantly influence blood glucose levels.

34 mportant, opposing roles in regulating blood glucose levels.

35 ches, leading to a gradual decrease in blood glucose levels.

36 ABA release to POMC neurons is influenced by glucose levels.

37 nabling the coupling of insulin secretion to glucose levels.

38 oid receptor blockade lowered elevated blood glucose levels.

39 pk-dependent pathway to lower HGP and plasma glucose levels.

40 were equally efficacious in reducing plasma glucose levels.

41 dinates transcriptional response to elevated glucose levels.

42 f glucagon and insulin at basal and elevated glucose levels.

43 olymorphisms, circulating CRP, diabetes, and glucose levels.

44 ecreased alpha-cell function, and thus lower glucose levels.

45 preoperative HbA1c levels and postoperative glucose levels.

46 l, high-density lipoprotein cholesterol, and glucose levels.

47 stasis of hepatic glycogen storage and blood glucose levels.

48 s effects to raise BP and reduce insulin and glucose levels.

49 vated blood pressure (49%), impaired fasting glucose levels (26%), and diabetes mellitus (14%).

50 reater than 70 mg/dL, 519 (52.6%) had normal glucose levels, 267 (27.1%) had mild, and 201 (20.4%) se

51 uivalent day 2 insulin (93 +/- 6 pmol/L) and glucose levels (5.3 +/- 0.1 mmol/L), plasma epinephrine,

52 tivity (AAV mice) produce endogenous hepatic glucose levels 61-68% of wild-type littermates, have a l

53 nction (E/E' 14 +/- 1), and normalized blood glucose levels (7.5 +/- 0.7 mmol/L).

54 insulin therapy (IIT) targeting normal blood glucose levels (81-108 mg/dl) increases the incidence of

55 gR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin le

56 HT decreased blood glucose levels, adipocyte size, and triglyceride accumul

57 ntly, NT-ES-beta-cells maintain normal blood glucose levels after ablation of the mouse endogenous be

58 0.20; 95% CI, 0.02 to 0.38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hed

59 ces in fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fas

60 ing on fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fas

61 Early lactate and glucose levels after aneurysmal subarachnoid hemorrhage

62 esponses (P=0.03-0.001) and decreased plasma glucose levels after glucose ingestion (P=0.02) with mor

63 with glucose dehydrogenase to regulate blood glucose level, alcohol dissolution into carboxylic acid

64 is far superior to measuring fasting plasma glucose levels alone.

65 us, and durable dose-dependent reductions in glucose levels along with significant increases in insul

66 A lowered blood glucose level also was observed in overnight-fasted, str

67 Glucose levels also improved spontaneously by 1 year of

68 arily susceptible to necroptosis, that local glucose levels alter the balance of PCD pathways, and th

69 HbA1c for given levels of fasting or 2-hour glucose levels among African Americans.

70 hat plays an important role regulating blood glucose levels, analogues of which are used for treatmen

71 hile physiological effects, including plasma glucose level and blood leukocyte numbers were significa

72 splay resistance to T1D as the rise in blood glucose level and islet inflammation were significantly

73 g survival, bodyweight, food intake, fasting glucose levels and age-related morbidity.

74 that hepatic GCN5L1 ablation reduces fasting glucose levels and blunts hepatic gluconeogenesis withou

75 importance of the brain in controlling both glucose levels and body weight, we hypothesized that act

76 Fasting glucose levels and carotid ultrasonography measures were

77 benefits, the significance of abnormal blood glucose levels and diabetes as cardiovascular risk facto

78 Blood glucose levels and disease severities were analyzed.

79 gnificant changes from baseline in lipid and glucose levels and extrapyramidal symptom ratings.

80 ntly observed that GBP patients have lowered glucose levels and frequent asymptomatic hypoglycemic ep

81 e in the NAc bidirectionally modulated blood glucose levels and glucose tolerance.

82 onstrate good correlation of reference blood glucose levels and glucose values obtained with the pres

83 licate NAc D2R in regulating both peripheral glucose levels and glucose-dependent reinforcement learn

84 Reductions in fasting glucose levels and hemoglobin A1c were greater after dis

85 M and AHINREM with fasting and post-prandial glucose levels and HOMA-IR.

86 Primary outcomes were glucose levels and incidence of hypoglycemia.

87 we show that 13d significantly lowers blood glucose levels and increases concomitant beta-cell survi

88 ivo, constitutively active YAP lowers plasma glucose levels and increases liver size.

89 Although near-normal glucose levels and insulin independence can be maintaine

90 ilation and CO2 sensitivity to restore blood glucose levels and prevent a fall in blood pH.

91 Fasting reduces glucose levels and protects mice against chemotoxicity,

92 verted "U-shape" fashion dependent on plasma glucose levels and related to metabolic states.SIGNIFICA

93 insulin release are entrained to oscillatory glucose levels and that the temporal correlation of thes

94 culature that affect the regulation of blood glucose levels and the development of atherosclerosis.

95 might be partially responsible for increased glucose levels and type 2 diabetes risk, which is consis

96 ngly, the Rosa-Lkb1 mice had increased blood glucose levels and were intolerant to glucose challenge.

97 d significant alterations, displaying higher glucose-levels and insulin-resistance.

98 esponsiveness, admission Glasgow Coma Scale, glucose level, and hemoglobin level) and used in univari

99 graphic data, blood pressures, fasting blood glucose level, and lipid profile.

100 triglyceride levels, 4.1-mg/dL higher 2-hour glucose levels, and 2.1-mm Hg higher systolic blood pres

101 nd 8-OHdG, low-density lipoprotein and blood glucose levels, and duration of diabetes in patients wit

102 Abnormal blood pressure, blood glucose levels, and fever in the setting of arterial isc

103 Abnormalities of blood pressure, blood glucose levels, and temperature are prevalent in childre

104 medical management of blood pressure, blood glucose levels, and temperature in pediatric patients af

105 r hormonal control of blood volume and blood glucose levels, and thus adding to our understanding of

106 Increased glucose levels are associated with the generation of adv

107 ced at TNZ, while its effects on insulin and glucose levels are attenuated and its effects on BP and

108 revious work in prostate cancer showing that glucose levels are high while citrate is low, we found t

109 cates that pre-diagnostic diabetes and blood glucose levels are inversely related to glioma risk.

110 ctivity persist, and relatively normal blood glucose levels are maintained.

111 tive hemoglobin A1c (HbA1c) or postoperative glucose levels are more useful in predicting adverse eve

112 Blood glucose levels are tightly controlled by the coordinated

113 ray and white matter in children whose blood glucose levels are well within the current treatment gui

114 % degree of gelatinization and maximal blood glucose level at 30min).

115 n ( approximately 53.8%) and a maximal blood glucose level at 60min (slower glycemic response) than a

116 The individual's blood glucose level at the time of obtaining saliva was also m

117 ation with diabetes, the change in the blood glucose level at the time of scan across longitudinal ti

118 Higher blood glucose levels at admission and during the first 36 hour

119 hi can act as "metabolic sinks" by depleting glucose levels at the implanted sensors in vitro and in

120 ts then underwent treatment to control blood glucose levels before end blood samples were taken.

121 s of severe hypoglycemia, defined as a blood glucose level below 40 mg per deciliter (2.2 mmol per li

122 2.2 +/- 0.44 kg/m(2) in persons with fasting glucose levels below and above the median, respectively.

123 a, 0.05; 95% CI, 0.00289 to .0981), and high glucose level (beta, 0.00179; 95% CI, 0.0006 to 0.00299)

124 this, with a steeper increase of the fasting glucose level (beta=131; 95% CI 38-225) during follow-up

125 % CI, 0.14-1.72; P = 0.02) and post-prandial glucose levels (beta = 3.0; 95% CI, 0.5-5.5; P = 0.02).

126 Blood glucose level (BGL), National Institute of Health Stroke

127 d lower very-low-density lipoprotein lipids, glucose levels, branched-chain amino acids, and inflamma

128 CREBH deficiency leads to reduced blood glucose levels but increases hepatic glycogen levels dur

129 udies associated CRP level with diabetes and glucose levels, but the association of CRP gene with the

130 GLP-1 is capable of regulating the blood glucose level by insulin secretion after administration

131 Pancreatic islets manage elevations in blood glucose level by secreting insulin into the bloodstream

132 city can be reversed by reducing circulating glucose levels by fasting or insulin.

133 Metformin lowers blood glucose levels by inhibiting hepatic glucose production

134 se homeostasis in vivo Nrf2 suppresses blood glucose levels by protecting pancreatic beta cells from

135 course of HSV infection and that modulating glucose levels can influence the outcome of infection, b

136 act of a given meal on an individual's blood glucose levels can serve as the engine for a new generat

137 t, we make the unexpected finding that blood glucose levels change significantly during the course of

138 Blood glucose levels changed in accordance with how much time

139 waves in transmission mode that can measure glucose level changes based on the complex permittivity

140 was associated with increased postoperative glucose level checks and insulin use, suggesting that he

141 In response to glucose levels, ChREBP is regulated by nuclear/cytosol t

142 ly chick embryo, we found that inducing high glucose levels could inhibit the development of CNCC, ho

143 Only 8% monitored their blood glucose levels daily, 15% monitored weekly, and 10% repo

144 roblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorated path

145 diabetes in patients who have abnormal blood glucose levels detected by screening.

146 rgin evaluation, bone disorder detection and glucose level determination.

147 lotype had higher plasma CHGA levels, plasma glucose levels, diastolic blood pressure, and body mass

148 lphonylurea therapy rapidly normalizes blood glucose levels, dissipates glycogen stores, increases au

149 metabolic (GAL) genes are induced only when glucose levels drop below a threshold.

150 Maternal glucose levels during pregnancy impact the developing fe

151 s and overexpression increases intracellular glucose levels during unfavorable conditions, including

152 C-reactive protein levels, impaired fasting glucose levels, dyslipidemia, elevated blood pressure, a

153 The risk of impaired fasting glucose levels, elevated blood pressure, and elevated hi

154 we show that human podocytes exposed to high glucose levels exhibited elevated expression of SHP-1, w

155 We have shown previously that high glucose level exposure and diabetes increased the expres

156 L to 3mmol/L, which covers the range of tear glucose levels for both diabetics and healthy subjects.

157 was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitud

158 ely four days and sustained control of blood glucose levels for more than a week in mice.

159 ssfully normalized and maintained host blood glucose levels for over 370 days in the absence of immun

160 glucose monitor for continuous monitoring of glucose levels for people living with diabetes, as it ca

161 f preoperative HbA1c and early postoperative glucose levels for predicting postoperative complication

162 Of 987 sepsis patients with admission glucose levels greater than 70 mg/dL, 519 (52.6%) had no

163 We defined diabetes as a fasting glucose level >/=126 mg/L (or >/=200 mg/L for those not

164 e, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles per l

165 Salivary glucose levels >1.13 mg/dL predicted gingivitis ( P < 0.

166 High glucose level (>/=6.11mmol/L) was associated with a lowe

167 ased likelihood of surgical site occurrence (glucose level, >/=140 vs <140 mg/dL: 37.5% [21 of 56 pat

168 ays in the interval to the first solid meal (glucose level, >/=140 vs <140 mg/dL: mean [SD] delay, 6.

169 < .001); increased costs of hospitalization (glucose level, >/=140 vs <140 mg/dL: mean [SD], $31307 [

170 4] days; P = .02); increased length of stay (glucose level, >/=140 vs <140 mg/dL: mean [SD], 8.0 [6.0

171 ht glycemic control targeting a normal blood glucose level has not been shown to improve outcomes in

172 In previous work, sinusoidal glucose levels have been used to test the entrainment of

173 ration, being under insulin treatment, blood glucose level, having non-communicable diseases were sig

174 Fasting plasma glucose levels (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P

175 nt gemcitabine (n = 107) with elevated serum glucose levels (HgbA1C > 6.5%) exhibited improved surviv

176 Lower fasting blood glucose levels, higher insulin, and lower islet amyloid

177 excretion, glomerular hyperfiltration, blood glucose levels, histological deterioration and systolic

178 (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.39), and hyper

179 umin and urea secretion were not affected by glucose level, hypoglycemic MPCCs upregulated CYP3A4 enz

180 (GOD), the AR/CoOxH-GO system can determine glucose level in blood samples.

181 ccessfully in preparing biosensors to detect glucose level in blood serum, urea level in urine soluti

182 emerged as a promising way to control blood glucose level in diabetes patients.

183 d to improve liver glycogen storage and sera glucose level in mice expressing human AATZ mice.

184 hether perceived time has an effect on blood glucose level in people with type 2 diabetes.

185 globin (HbA1c), reflecting the average blood glucose level in the proceeding 2-3 months, is recommend

186 s, the proportion of time with the nighttime glucose level in the target range was higher during the

187 Leptin treatment normalized blood glucose levels in both groups.

188 n the fasting state is followed by increased glucose levels in both sweat and blood.

189 matter volumes, suggesting that fluctuating glucose levels in children with diabetes may be associat

190 tuated to deliver Metformin and reduce blood glucose levels in diabetic mice.

191 nistration lowered random as well as fasting glucose levels in diabetic mice.

192 short-term transplantation, and reduce blood glucose levels in diabetic mice.

193 ared as viable therapeutics to control blood glucose levels in diabetic patents.

194 e non-invasive and on-body quantification of glucose levels in human perspiration.

195 ompound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge,

196 A normal response to altering directly CNS glucose levels in mice lacking astrocytic IRs indicates

197 em in motion sickness and suggest a role for glucose levels in motion-induced nausea and vomiting, a

198 sEPD of insulin was found to maintain blood glucose levels in normal range for at least 6h in chemic

199 cutaneous injection failed to maintain blood glucose levels in normal range.

200 ble human intake (3-40 mug/kg) on oxygen and glucose levels in nucleus accumbens (NAc).

201 GOx-PLDz 1.0 biosensor is able to determine glucose levels in tears and saliva as a noninvasive gluc

202 ses from a dysregulated response to elevated glucose levels in the circulation.

203 High glucose levels in the peripheral nervous system (PNS) ha

204 eatment significantly reduced fasting plasma glucose levels in the rats with DM.

205 excited or inhibited by 5-HT at hypoglycemic glucose levels in vitro.

206 ro translated into the efficient lowering of glucose levels in vivo with the best compounds.

207 r for glucose detection in tears and saliva, glucose levels in which are 720+/-81 muM and 405+/-56 mu

208 Deviation from normal glucose levels, in either direction, increases susceptib

209 In cultured podocytes, high glucose levels increased mRNA, protein expression, and p

210 glucose administration under similar plasma glucose levels (incretin effect).

211 We could show that glucose levels influenced the extent of induction of the

212 in receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in o

213 Control of plasma glucose level is essential to organismal survival.

214 etabolic environment to regulate circulating glucose levels is ill defined.

215 tes mellitus (types 1 and 2), an increase in glucose levels is likely, and diabetes medication adjust

216 ater (>/=225 mg/dL) (hyperglycemic) and/or a glucose level less than 3.9 mmol/L (<70 mg/dL) (hypoglyc

217 LQT2 patients developed hypoglycemic plasma glucose levels (<70 mg/dL) versus 36% control participan

218 Higher fasting glucose levels may amplify obesity-risk in FTO carriers

219 idome between participants with normal blood glucose levels (n = 26) and those with type 2 diabetes (

220 d podocytes, which remained elevated despite glucose level normalization.

221 Hyperglycemia was defined as a blood glucose level of 200 mg/dL or greater.

222 rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter

223 m tight glycemic control targeted to a blood glucose level of 80 to 110 mg per deciliter, as compared

224 ty-four patients (39.7%) had a postoperative glucose level of at least 140 mg/dL, and 69 patients (50

225 Diabetes was defined as a random glucose level of at least 200 mg/dL, hemoglobin A1c conc

226 8) We suggest that clinicians target a blood glucose level of less than 180 mg/dL in patients receivi

227 n page 3115, effectively regulates the blood glucose level of type-1 diabetic mice, achieving a reduc

228 orily, which is well below the typical human glucose levels of 4 mmol/l.

229 t and procedural factors, peak postoperative glucose levels of more than 250 mg/dL were associated wi

230 investigate the effect of sleep and salivary glucose levels on the development of gingivitis in a pro

231 meliorated hepatosteatosis but did not alter glucose levels or body weight in lean controls.

232 sideration is whether screening for abnormal glucose levels or diabetes reduces cardiovascular or all

233 with lung function, haemoglobin, creatinine, glucose levels or resting blood pressure measures.

234 e hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes to behavioral counseling to

235 (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes).

236 s not appear to regulate energy stores, free glucose levels, or feeding behavior suggesting the sleep

237 identified by fasting or non-fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin

238 ir insulin secretory response to stimulatory glucose levels (P < 0.01).

239 e significantly associated with higher blood glucose levels (P = 3.9E(-4)).

240 in resistance (P for trend<0.001) and 2-hour glucose levels (P for trend=0.015).

241 Overriding IR in an effort to lower plasma glucose levels, particularly with intensive insulin ther

242 It is known that even normal blood glucose levels physiologically inhibit glycogen phosphor

243 ndardized mean differences in fasting plasma glucose levels, plasma glucose levels after an oral gluc

244 -control studies reporting on fasting plasma glucose levels, plasma glucose levels after an oral gluc

245 ecrete insulin in response to an increase in glucose levels, play a significant role in glucose homeo

246 on models adjusting for HbA1c, postoperative glucose levels, postoperative insulin use, diabetes, bod

247 During hypoglycemia, glucose levels reached a nadir of approximately 2.0 mmol

248 uggest a mechanism whereby oscillatory blood glucose levels recruit non-oscillating islets to enhance

249 In contrast to the RSS1 and RSS3 conditions, glucose levels reduced more quickly for the DSS conditio

250 tively, an up-regulation of genes related to glucose level reduction and concomitantly reduced appeti

251 se concentrations in the circulation whereas glucose levels remained elevated in both single cultures

252 ctive oxygen species production, while blood glucose levels remained unchanged.

253 Furthermore, high glucose levels repressed F4969 culture sialidase activit

254 associated with type 2 diabetes and fasting glucose levels reside in introns of ADCY5, a gene that e

255 When blood glucose levels return to normoglycemia beta-cell mass ex

256 Glucose levels significantly decreased and lactate level

257 taining a close correlation with their blood glucose levels, simplifying and reducing the costs of th

258 ime will have a greater influence over blood glucose level than actual time.

259 Glu-OC experienced significantly lower blood glucose levels than Glu-OCN-treated wild-type mice.

260 s2(+/Akita) mice showed a reduction in blood glucose levels that correlated with the amelioration of

261 its conformation in response to cytoplasmic glucose levels that regulate its interaction with Mig1 a

262 ngerhans are the regulators of in vivo blood glucose levels through the secretion of endocrine hormon

263 lin in response to postprandial increases in glucose levels to prevent hyperglycemia and inhibit insu

264 DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significa

265 The authors demonstrate that high blood glucose levels trigger neutrophil release of S100 calciu

266 hours and remained responsive to changes in glucose levels unlike non-encapsulated controls.

267 the target range 68.7% of the time; the mean glucose level was 126 mg per deciliter (7.0 mmol per lit

268 mong adults, the proportion of time that the glucose level was in the target range was 11.0 percentag

269 .6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per decilite

270 The overnight mean glucose level was lower during closed-loop therapy than

271 Reduction in 2-hour glucose level was restricted to high-intensity exercise.

272 each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec gr

273 l analyses, the median time-weighted average glucose level was significantly lower in the lower-targe

274 podocytes despite normalization of systemic glucose levels was associated with sustained inhibition

275 ustment for covariates, reductions in 2-hour glucose level were greater in the HAHI group (-0.7 mmol/

276 Fasting and 2-hour post-challenge glucose levels were assessed during a glucose tolerance

277 g diabetes, several combinations of abnormal glucose levels were associated with increased 90-day mor

278 l therapy in the percentage of time in which glucose levels were below the target range (1.3% and 1.9

279 t shorter sleep duration and higher salivary glucose levels were both associated with increased gingi

280 increase in the HDL/LDL ratio, and improved glucose levels were documented.

281 atal hospitalizations, labor, and delivery), glucose levels were in the target range 68.7% of the tim

282 The percentage of time that overnight glucose levels were in the target range was higher durin

283 As expected, pre-diagnostic blood glucose levels were inversely related to glioma risk (AM

284 ve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lo

285 Salivary glucose levels were measured by a florescent glucose oxi

286 Lactate, pyruvate and glucose levels were measured continuously using microdia

287 Changes in blood glucose levels were measured in 46 participants with dia

288 database, nutritional information, and blood glucose levels were merged for analysis.

289 Body weights, blood glucose levels were monitored throughout the study.

290 In Keap1MuKO mice, blood glucose levels were significantly downregulated and the

291 me was the percentage of time that overnight glucose levels were within the target range (63 to 140 m

292 0 treatment significantly improved the blood glucose levels when compared to those of control animals

293 licited a rapid decline in circulating blood glucose levels, which appeared to induce endogenous gluc

294 tal bone development in the presence of high glucose levels, which is derived from cranial neural cre

295 h lowered insulin secretion, increases serum glucose levels, which stimulates de novo lipogenesis (DN

296 Normalization of blood glucose levels with GCGR-blocking antibody unexpectedly

297 ase was associated with improvement in blood glucose levels, with evidence of altered expression of g

298 within 90 days and the highest postoperative glucose levels within 48 hours of undergoing surgery.

299 creas to reliably and automatically maintain glucose levels within a tight range.

300 In 285 patients, maximal lactate and glucose levels within the first 24 hours after admission